Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
The Central Social Insurance Medical Council (Chuikyo) approved basically a draft framework for “patient-initiated mixed care” that the Ministry of Health, Labor and Welfare (MHLW) presented at a general meeting on September 30. Patient-initiated mixed care will be introduced next…
To read the full story
Related Article
- MHLW Council to Draft Negotiation Rules on Supply of Unapproved Drugs under Patient-Initiated Mix Care Scheme
March 18, 2019
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
- FY2015 Survey on Generic Use to Get Underway, Results Out in Autumn
July 9, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- Chuikyo OKs Patient-Initiated Mixed-Care System, Use of Investigational Drugs for Non-Enrollable Patients
November 7, 2014
- Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Govt Deregulation Panel Pushes New System to Allow Mixed Care at Patient Request
March 31, 2014
REGULATORY
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
- Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
April 27, 2026
- Nitrosamines Found in Duloxetine, Diltiazem; Panel Sets Intake Limits
April 27, 2026
- Health Insurance Reform Bill Clears Lower House Committee, Draws Backlash
April 27, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…